ATP23 gRNA (BRDN0001148186) Citations (1)
Originally described in: Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9.Doench JG, Fusi N, Sullender M, Hegde M, Vaimberg EW, Donovan KF, Smith I, Tothova Z, Wilen C, Orchard R, Virgin HW, Listgarten J, Root DE Nat Biotechnol. 2016 Jan 18. doi: 10.1038/nbt.3437. PubMed Journal
Articles Citing ATP23 gRNA (BRDN0001148186)
| Articles |
|---|
| Therapeutic Efficacy of Immune Stimulatory Thymidine Kinase and fms-like Tyrosine Kinase 3 Ligand (TK/Flt3L) Gene Therapy in a Mouse Model of High-Grade Brainstem Glioma. Mendez F, Kadiyala P, Nunez FJ, Carney S, Nunez FM, Gauss JC, Ravindran R, Pawar S, Edwards M, Garcia-Fabiani MB, Haase S, Lowenstein PR, Castro MG. Clin Cancer Res. 2020 Aug 1;26(15):4080-4092. doi: 10.1158/1078-0432.CCR-19-3714. Epub 2020 Apr 24. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.